Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MCAC Referral Draft Guidelines Need Clarity, More Specificity – AdvaMed

This article was originally published in The Gray Sheet

Executive Summary

Guidelines specifying how the public can best frame evidentiary questions used in MCAC review should be included in a 1CMS draft guidance stipulating criteria for when an NCD should be referred to the committee, AdvaMed maintains

You may also be interested in...



Draft Guidance On NCD MCAC Referral Has Ongoing Comment Period

Industry reps plan to hold a conference call within the next several weeks to discuss a 1CMS draft guidance stipulating criteria for when national coverage determinations should be referred for external review or to the Medicare Coverage Advisory Committee

MCAC Supports MADIT-II Criteria; EP Testing Scuttled As Stratification Tool

Guidant's subgroup analysis demonstrating that non-inducible EP-tested patients showed lower mortality rates with ICDs over conventional therapy played a decisive factor in MCAC's endorsement of national coverage

Atlas Biomed Unlocking Japan’s OTC Market With Direct-To-Consumer DNA And Microbiome Tests

Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus. 

UsernamePublicRestriction

Register

OM014142

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel